enGene Therapeutics Inc. ENGN
enGene Holdings Inc. (together with its consolidated subsidiaries "enGene" or the "Company") formed in connection with the Merger Agreement (as defined below), was incorporated as 14963148 Canada Inc. under the federal laws of Canada on April 24, 2023 and changed its name to enGene Holdings Inc. on May 9, 2023. On October 31, 2023, enGene Holdings Inc. continued from being a corporation incorporated under and governed by the Canada Business Corporations Act to a company continued to and governed by the Business Corporations Act (British Columbia).
Forbion European Acquisition Corporation ("FEAC") was a special purpose acquisition company ("SPAC"), incorporated as a Cayman Island exempted company on August 9, 2021 and formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more business or entities. On October 31, 2023 (the "Closing Date"), the Company, FEAC, and enGene Inc., a subsidiary of the Company, consummated the merger (the "Reverse Recapitalization" or the "Business Combination") pursuant to a business combination agreement, dated as of May 16, 2023 (the "Merger Agreement").
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D | $94.5M | $38.3M | $16.5M | $15.5M | — |
| SG&A | $28.7M | $24.0M | $9.6M | $4.0M | — |
| Total operating expenses | $123.2M | $62.3M | $26.1M | $19.4M | — |
| Operating income | -$123.2M | -$62.3M | -$26.1M | -$19.4M | — |
| Interest expense | $3.0M | $2.8M | $5.0M | $1.4M | — |
| Pre-tax income | -$117.3M | -$55.2M | -$99.9M | -$24.4M | — |
| Income tax | $0 | $19.0K | $17.0K | $22.0K | — |
| Net income | -$117.3M | -$55.1M | -$99.9M | -$24.5M | — |
| EPS, basic | 2.29 | 1.46 | 151.22 | 44.30 | — |
| EPS, diluted | 2.29 | 1.46 | 151.22 | 44.30 | — |
| Shares, diluted (wtd. avg.) | 51.1M | 37.8M | 692,609 | 655,153 | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash and equivalents | $50.2M | $173.0M | $81.5M | $20.4M | $11.0M |
| Short-term investments | $143.6M | $65.3M | — | — | — |
| Total current assets | $201.4M | $247.4M | $85.4M | $22.6M | — |
| Property, plant and equipment | $2.5M | $1.2M | $589.0K | $387.0K | — |
| Total assets | $221.5M | $311.2M | $87.0M | $23.9M | — |
| Accounts payable | $6.7M | $1.4M | $1.2M | $723.0K | — |
| Total current liabilities | $32.0M | $14.7M | $5.3M | $5.1M | — |
| Total liabilities | $53.8M | $38.6M | $14.5M | $47.4M | — |
| Retained earnings | -$372.0M | -$254.7M | -$199.6M | -$99.7M | — |
| Total equity | $167.7M | $272.6M | $72.5M | -$76.6M | -$53.4M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$99.2M | -$48.3M | -$24.7M | -$17.6M | — |
| Depreciation and amortisation | $500.0K | $300.0K | $200.0K | $200.0K | — |
| Stock-based compensation | $9.6M | $5.3M | $3.5M | $116.0K | — |
| Capital expenditure | $1.5M | $925.0K | $318.0K | $153.0K | — |
| Investing cash flow | -$25.1M | -$126.0M | -$318.0K | -$153.0K | — |
| Financing cash flow | $1.5M | $265.7M | $86.1M | $28.0M | — |
| Dividends paid | — | — | $0 | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-059409.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Net income | — | -$24.5M | -$99.9M | -$55.1M | -$117.3M |
Recent filings and events
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Regulation FD disclosure Item 7.01
- Restructuring or exit costs A restructuring: layoffs, a plant closure, a business being wound down. Item 2.05
- Officer or director change Item 5.02
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Restructuring or exit costs Item 2.05
- Officer or director change Item 5.02
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |